Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276) has announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its investigational drug SHR-2106, targeting active primary Sjögren’s syndrome (pSS).
Primary Sjögren’s syndrome is a chronic autoimmune disorder predominantly affecting middle-aged and elderly women, characterized by lymphocyte proliferation and progressive damage to exocrine glands. Patients typically experience symptoms such as dry mouth and eyes, pain, and fatigue. The condition can also impact various other organs and systems, and effective treatments remain elusive, with current options largely based on empirical therapies.
SHR-2106 is a novel monoclonal antibody developed in-house, notable for being the first of its kind to seek approval globally. It was previously cleared for clinical study aimed at preventing graft rejection in organ transplantation, showcasing its therapeutic potential.- Flcube.com
